UPDATE: Stifel Nicolaus Initiates Buy, $16 PT on NewLink Genetics

Stifel Nicolaus initiates its coverage on NewLink Genetics NLNK with a Buy rating and a $16 target price as the company presents a new approach to immunotherapy. Stifel Nicolaus says, "We believe HyperAcute's ability to simultaneously present the immune system with multiple tumor associated antigens in an earlier stage of disease that allows the immune system to become an activated surveillance system – and doesn't require it to become an active killer of distal metastases – provides a strong biological rationale for efficacy." NLNK closed at $7 per share on Tuesday